Direct Stenting Versus Direct Stenting Followed by Centered Beta-Radiation With Intravascular Ultrasound-Guided Dosimetry and Long-Term Anti-Platelet Treatment Results of a Randomized Trial: Beta-Radiation Investigation With Direct Stenting and Galileo in Europe (BRIDGE) by Serruys, Patrick W. et al.
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OBJECTIVES We sought to assess the efficacy of vascular brachytherapy (VBT) combined with stenting for
the primary prevention of restenosis.
BACKGROUND Intravascular brachytherapy after stent implantation for de novo lesions has been abandoned
for the present. We revisited this procedure by optimizing all procedural steps—the use of
glycoprotein IIb/IIIa blockers, direct stenting, adequate radiation coverage, avoidance of edge
damage, source centering, intravascular ultrasound-guided dosimetry, and continuation of a
dual anti-platelet regimen for one year.
METHODS The Beta-Radiation Investigation with Direct stenting and Galileo in Europe (BRIDGE)
study is a multicenter, randomized controlled trial evaluating the long-term efficacy of VBT
with P-32 (20 Gy at 1 mm in the coronary wall) after direct stenting. The primary end point
was angiographic intra-stent late loss; secondary end points were six months binary restenosis
and neo-intimal hyperplasia. Patients (n  112) with de novo lesions (2.5 to 4.0 mm in
diameter up to 15 mm long) were randomized to either VBT or no-VBT.
RESULTS At six months, intra-stent loss was 0.43 and 0.84 mm (p  0.001) in the irradiated and
control groups, respectively. Intra-stent neo-intimal volume was reduced from 36 mm3 to 10
mm3. However, in the irradiated group there were six late occlusions as well as eight
restenoses outside the stented and peri-stented area at the fall-off dose edges of the irradiated
area. Accordingly, the target vessel revascularization and major adverse cardiac and cerebro-
vascular events rates at one year in the VBT group (20.4% and 25.9%, respectively) were
higher than in the control group (12.1% and 17.2%, respectively).
CONCLUSIONS Despite the optimization of pre-, peri-, and post-procedural factors and despite the relative
efficacy of the brachytherapy for the prevention of the intra-stent neo-intimal hyperplasia, the
clinical outcome of the irradiated group was less favorable than that of the control
group. (J Am Coll Cardiol 2004;44:528–37) © 2004 by the American College of
Cardiology Foundationf
o
d
(
o
f
f
n
a
l
o
w
rt has been shown that stents reduce restenosis by eliminat-
ng elastic recoil and negative remodeling, but they induce
eo-intimal hyperplasia (1). Several randomized studies
See page 538
ave confirmed the effectiveness of vascular brachytherapy
VBT) for the treatment of in-stent restenosis both with
amma (2–4) and beta (5–7) emitters, but its effectiveness
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Manuscript received November 21, 2003; revised manuscript received March 1,c004, accepted March 2, 2004.or de novo lesions, especially in combination with the use
f stents, remains contentious (8–10).
A dose-finding study with yttrium demonstrated a dose-
ependent reduction in restenosis in non-stented arteries
8), probably resulting from a beneficial effect of radiation
n remodeling and an inhibitory effect on neo-intima
ormation (11,12). This trial, however, did not suggest any
avorable impact of beta radiation on restenosis in stented de
ovo lesions. Restenosis adjacent to the target site (13,14)
nd late thrombotic events (15) were recognized as major
imitations of VBT, especially in combination with the use
f stents (9,10).
Geographical miss (GM) and edge restenosis frequently
ere associated with dilation and stenting occurring after
adiation treatment (16). Therefore, it was advocated to
omplete the percutaneous intervention treatment prior to
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August 4, 2004:528–37 The BRIDGE Trialadiation to ensure complete radiotherapy coverage of the
njury. Accordingly, direct stenting was viewed as an opti-
al approach to minimize the incidence of GM and edge
estenosis. In addition, source centering and intravascular
ltrasound (IVUS)-guided dosimetry, with theoretical ad-
antages on dose delivery, were viewed as the methods of
hoice for radiotherapy treatment.
Because animal data have demonstrated increased throm-
osis and the early presence of platelet activation after
rachytherapy (17), the use of glycoprotein IIb/IIIa inhib-
tors was recommended as adjunctive therapy. Finally it was
ypothesized that prolonged use of a dual anti-platelet
edication reduces the incidence of late silent or throm-
otic vessel occlusion (9,10,18,19). Thus, the purpose of the
urrent study was to evaluate the efficacy of centered
ntra-coronary beta irradiation with 32P/Galileo after direct
tenting of de novo lesions in patients undergoing extended
nti-platelet treatment with aspirin and clopidogrel.
ETHODS
tudy design. The Beta-Radiation Investigation with Di-
ect stenting and Galileo in Europe (BRIDGE) trial is a
ulticenter, randomized, controlled clinical trial on the
ffect of brachytherapy after direct stenting. From February
001 until March 2002, 112 patients were enrolled at 8
uropean centers. If the patient was eligible, a phone call
as made to the central allocation service to register the
atient, and the direct stenting procedure was performed. In
ases of edge dissection or a stented length 18 mm,
atients were subsequently not randomized. Once the direct
tenting result was optimal based on quantitative coronary
ngiography (QCA) online criteria (residual diameter ste-
osis 15%), IVUS assessment was performed, and the
atient was randomized during a second phone call, to
ither the VBT or control group.
All randomized patients underwent clinical follow-up at
, 6, and 12 months and angiographic and IVUS follow-up
t 6 months. An independent core laboratory assessed the
ngiographic and IVUS outcomes. Clinical end points were
ssessed by an independent masked end point committee.
n independent data safety monitoring committee assessed
he results with respect to patient safety at regular intervals.
nd points. The primary end point was the angiographic
Abbreviations and Acronyms
EIRS  effective irradiated segment
GM  geographical miss
IVUS  intravascular ultrasound
MACCE  major adverse cardiac and cerebrovascular
events
MI  myocardial infarction
MLD  minimal luminal diameter
QCA  quantitative coronary angiography
VBT  vascular brachytherapyntra-stent late loss. The secondary end points were event- tree survival at one year, defined as the absence of major
dverse cardiac and cerebrovascular events (MACCE). Ma-
or adverse cardiac and cerebrovascular events were defined
s the occurrence of cardiac death and/or cerebrovascular
vents and/or myocardial infarction (MI) (Q-wave infarc-
ion as defined by Minnesota Code, non–Q-wave MI two
imes the upper limit of normal of creatine kinase and an
bnormal level of creatine kinase, MB fraction) and/or
arget vessel revascularization.
All deaths were considered cardiac unless they were
nequivocally documented to be non-cardiac. “Target lesion
evascularization” was defined as revascularization of the
tented segment. “Target vessel revascularization” was de-
ned as a revascularization of any segment of the random-
zed coronary artery. Additional secondary end points were
ACCE, binary angiographic restenosis at six months, and
eo-intimal hyperplasia at six months as assessed by IVUS.
ower calculation and sample size. The sample size
alculations were based on the results of the BElgium
Etherlands STENT (BENESTENT) II trial and the
esults of the dose-finding studies with the device under
nvestigation (8,20,21).
One hundred and twelve patients were randomized to
wo groups of equal size. This number of patients would
ead to a power of at least 84% to detect a 50% decrease in
oss (from 0.80 in the control group to 0.40 in the treated
roup) with a two-sided type I error rate of 0.05.
atient selection. Major inclusion criteria were: de novo
esions in one or two native vessels with a reference diameter
f 2.5 to 4.0 mm and a lesion length of 15 mm suitable for
irect stenting; stable (Canadian Cardiovascular Society
lass I, II, III, or IV) or unstable angina pectoris (Braunwald
lass I to III, B to C); or documented silent ischemia. Major
xclusion criteria were: any MI within three days before
nclusion and/or lack of normalization of the creatine
hosphokinase; previous Q-wave MI in the territory sup-
lied by the vessel to be treated and a large akinetic area in
he same territory; stroke/gastro-intestinal bleeding within
ix months; ejection fraction 30%; severe hepatic disease;
revious mediastinal irradiation; or known intolerance or
ontraindication to aspirin, clopidogrel, or glycoprotein
IB/IIIA inhibitors. Angioplasty exclusion criteria were:
otal occlusion (Thrombolysis in Myocardial Infarction flow
rade 0); stenting of each arm of a bifurcation; and intended
ngioplasty of the ostium of the left anterior descending and
eft circumflex coronary artery to avoid impeding the flow in
he main stem with the centering catheter. Written in-
ormed consent was obtained before patients were admitted
o the interventional suite.
ost-procedural anti-platelet treatment. By protocol, a
ual (clopidogrel 75 mg and acetylsalicylic acid 80 mg daily)
nti-platelet treatment was used up to 11 months.
tudy device: stent and radiation delivery system. The
8-mm MULTI-LINK RX TETRA Coronary Stent Sys-
em (Guidant, Santa Clara, California) was used for direct
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The BRIDGE Trial August 4, 2004:528–37tenting, and the GALILEO Intravascular Radiotherapy
ystem (Guidant) was used for VBT.
The GALILEO Intravascular Radiotherapy System
omprises the 32P 0.018-inch source wire, a centering
atheter, and the GALILEO source delivery unit. The
ource delivery unit is a high-dose rate afterloader designed
pecifically for coronary radiotherapy. It has a computer-
ontrolled source wire handling device, which automatically
dvances the source wire to the most distal position of the
entering catheter and subsequently moves to the next more
roximal position in 20-mm increments (known as “steps”).
hus, the source wire makes two steps within the 32-mm
ong spiral-designed centering balloon catheter that is in-
ated to a pressure of 4  1 atmospheres and has a nominal
iameter of 2.5, 3.0, or 3.5 mm. Radiopaque markers
proximal and distal to the balloon) allow for the precise
ositioning of the centering catheter at the lesion site.
The appropriate diameter of the centering catheter is
elected based on the intra-stent minimal luminal diameter
MLD) determined by online QCA. The dwell time re-
uired to deliver the prescribed dose (20 Gy at a depth of 1
m in the vessel wall) is automatically computed, based on
he average reference luminal diameter calculated from
roximal and distal MLD acquired from online IVUS
ssessment. The length of the artery receiving full 20 Gy at
mm is 32 mm, whereas the whole radiated length is 40
igure 1. A schematic diagram of the tandem positioning of the 32P radiat
ub-segment definition. BRM  balloon radiopaque marker; CB  center
rradiation length; EIRS  effective irradiated segment; INS  injured seg
L  stent length; SrL  source length; SrRM  source radiopaque mam (2  20 mm). Fractionation of the treatment was
equired in three patients.
CA evaluation. Quantitative coronary angiography was
erformed by means of the CAAS II analysis system (Pie
edical BV, Maastricht, Netherlands). A methodological
pproach, previously reported (9,14,16,22), was used to
ccurately depict the “geographic” relationship between the
tent and the radioactive source, and the following sub-
egments were defined (Fig. 1):
Stented segment—defined by the radiopacity of the
MULTI-LINK RX TETRA coronary stent.
Peri-stent segments—defined by a length of 5 mm
proximal and distal to the stent edge.
Irradiated segment—defined as the segment encom-
passed by the inner edge of the radiopaque markers of the
source wire. Two sub-segments of the irradiated segment
are identified:
1. Effective irradiated segment (EIRS)—the segment
(32 mm) receiving full prescribed therapeutic radia-
tion dose (90% isodose) is shorter than the irradiated
segment (40 mm) as a result of the dose fall-off.
2. Edge (dose fall-off) segments—vessel segments at the
extremities of the irradiation source that do not receive
the full therapeutic radiation dose. The length of each
urce and an irradiated coronary artery with the anatomical and dose-based
alloon; CBRM  centering balloon radiopaque marker; EIRL  effective
; IRL  irradiation length; IRS  irradiated segment; SB  side branch;
VS  vessel segment.ion so
ing b
mentedge segment is approximately 4 mm.
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August 4, 2004:528–37 The BRIDGE TrialVessel segment analysis—segment bordered by angio-
graphically visible side branches encompassing lesion,
stent, and radiation source.
GM segment—this segment is present when the length
of the stented and peri-stent segments (28 mm) are not
covered by the EIRS (Figs. 2 and 3).
he above segment lengths were automatically measured
y a customized software package specifically designed
or the assessment of brachytherapy treatment. With this
oftware, the anatomic relationship between the various
igure 2. An example of quantitative coronary angiography depicting the
he injured (B), and the irradiated (C) sub-segments, which allows the q
roximal edge in this case.
igure 3. Location of the minimal luminal diameter at six months follow
ose-based sub-segments. Four instances of late total occlusion (LTO) wer
IRS  effective irradiated segment; IRS  irradiated segment; VS  vessel sdose-related) sub-segments is automatically assessed,
llowing the quantitative assessment of the length of the
M (Fig. 2).
At follow-up, the detection of any diameter stenoses
50% in the analyzed vessel segment was performed by
nalysts who were blinded to the allocated treatment.
ubsequently, the boundaries of the above-mentioned sub-
egments were superimposed on matched angiographic
iews using transparent sheets to locate the site of the MLD
ith respect to the irradiated area (9,14,16,22).
atic assessment of the anatomic relationship between the obstructed (A),
ative assessment of the length of the geographical miss, 8.73 mm at the
(4 weeks) in patients with 50% diameter stenoses in relation to the
mented at the time of the angiographic follow-up, and two occurred later.autom
uantit-up
e docuegment.
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The BRIDGE Trial August 4, 2004:528–37uantitative IVUS. Post-procedure and six-month follow-
p stented vessel segments were examined with mechanical
ntravascular ultrasound (Cardio Vascular Imaging System,
VIS, Sunnyvale, California) using automated pullback at 0.5
m/s. A coronary segment beginning 5 mm distal to and
xtending 5 mm proximal to the stented segment also was
xamined. A computer-based contour detection program was
sed for automated three-dimensional reconstruction of the
tented segment. Lumen, stent boundaries, and external elastic
embrane were detected using a minimum-cost algorithm.
otal vessel volume (TVV), stent volume (SV), and lumen
olume (LV) were calculated according to Simpson’s rule.
otal plaque volume, plaque volume behind the stent struts,
nd neo-intimal hyperplasia were calculated as TVV  LV,
VV  SV, SV  LV, respectively. Percentage obstruction
olume was calculated as neo-intimal volume/stent volume 
00. Feasibility, reproducibility, and inter- and intra-observer
ariability of this system have been validated in vitro and in vivo
23,24).
tatistical analysis. The primary analysis was performed
ccording to the intention-to-treat principle (all random-
zed patients), and the QCA end point was assessed on a
er-lesion basis. A secondary per-protocol analysis was
erformed; patients who did not receive brachytherapy
reatment as planned were excluded.
Continuous parameters were presented as mean values and
tandard deviations, and discontinuous parameters as percent-
ges. Continuous parameters were compared using the Student
Table 1. Baseline Clinical and Angiographic C
(n  54
Age, yrs (mean  SD)
Gender, male
Previous MI
Diabetes mellitus
Hypertension
Current smoker
Angina pectoris*
CCS class I
CCS class II
CCS class III
CCS class IV
Glycoprotein IIb/IIIa inhibitors
Target coronary artery
LAD
RCA
LCX
Lesion type n
A
B1
B2
C
Reference vessel diameter (mm)
Lesion length (mm) 1
Plus-minus values are means SD. Unless indicated, all data
to the classification of the Canadian Cardiovascular Society
LAD  left anterior descending coronary artery; LCX
RCA  right coronary artery.test, whereas binary parameters were compared using the tisher exact test. Patient survival curves were constructed
ccording to the Kaplan-Meier method. The Wilcoxon rank
um test was applied to evaluate the difference in hierarchical
anking between the two groups. The statistical significance of
ll tests was defined at the p  0.05 level.
ESULTS
atient baseline characteristics. Table 1 shows the base-
ine clinical and angiographic characteristics of each study
roup (54 patients with 57 lesions in the irradiation group
ersus 58 patients with 59 lesions in the control group). The
umber of diabetic patients enrolled in the irradiated and
ontrol groups were 8 (14.8%) and 13 (22.4%), respectively.
he majority of patients were elective cases in functional
lass II or III, with a lesion Type B1/B2. In each group,
5% of the patients received abciximab.
erial QCA analyses. STENT AND PERI-STENT SEG-
ENTS. A total of 116 lesions were randomized: 57 lesions
ere allocated to irradiation, and 59 to control. Quantitative
ngiographic follow-up was available in 55 lesions allocated to
rradiation, and 53 allocated to conventional treatment. Three
esions in the irradiated group did not receive the allocated
reatment: one lesion could not be crossed with the delivery
atheter, one lesion could not be irradiated because of a
echnical defect, and one lesion occluded before irradiation. In
n intention-to-treat analysis, the in-stent late loss was reduced
rom 0.84  0.46 to 0.43  0.75 mm (p  0.001). Although
cteristics (Intention to Treat)
ation
ients), n (%)
No Irradiation
(n  58 Patients), n (%)
10.5 61.6  10.5
.9%) 48 (82.8%)
.6%) 19 (32.8%)
.8%) 13 (22.4%)
.3%) 31 (53.4%)
.6%) 12 (21.1%)
.1%) 5 (8.6%)
.9%) 19 (32.8%)
.5%) 15 (25.9%)
0%) 1 (1.7%)
.4%) 55 (94.8%)
.0%) 28 (48.3%)
.4%) 25 (43.1%)
.6%) 23 (39.7%)
lesions n  59 lesions
3%) 1 (1.7%)
.8%) 20 (33.9%)
.9%) 38 (64.4%)
0%) 0 (0.0%)
0.59 2.87  0.49
3.85 11.73  5.42
sented as percent of patients. *Angina was defined according
.
t circumflex coronary artery; MI  myocardial infarction;hara
Irradi
Pat
61.2 
41 (75
16 (29
8 (14
32 (59
12 (22
6 (11
21 (38
10 (18
0 (0.
51 (94
27 (50
31 (57
16 (29
 57
3 (5.
21 (36
33 (57
0 (0.
2.83 
1.50 
are pre
(CCS)
 lefhe primary end point of the study was reached, the in-stent
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August 4, 2004:528–37 The BRIDGE Trialestenosis rates were similar; 12.7% (7 of 55; including 4 total
cclusions) in the irradiated group versus 13.2% (7 of 53) in the
ontrol group. There was one patient with peri-stent restenosis
n the control group (proximal edge), increasing restenosis to
5.1%, and none in the irradiated group. The location of the
LD in patients with restenosis at follow up is presented in
igure 3.
If the three lesions that did not receive the irradiation
llocated treatment were deregistered from the intention-
o-treat analysis (per protocol analysis), then the late loss
as reduced to 0.38  0.71 mm and the restenosis rate to
.6%. Irradiation showed a beneficial effect in the intention-
o-treat group on the late luminal loss at the proximal edge
Table 2).
NALYZED VESSEL SEGMENT. At follow-up in the irradi-
ted group, four additional sites with a diameter stenosis
50% were found in the EIRS, whereas four other rest-
notic sites were located at the edges of the EIRS (dose
all-off segments; one proximal and three distal). This
esulted in an overall restenosis rate of 27.3%, whereas the
estenosis rate in the control group remained 15.1%, p 
.16 (no restenosis outside the stented and peri-stent
egments) (Fig. 3).
OTAL OCCLUSIONS. Overall, six patients presented with a
ate total occlusion (30 days), four within the time window
f angiographic follow-up (180 days  30 days; 103, 158,
69, and 171 days after irradiation) and two later (270 and
69 days after irradiation). In an intention-to-treat analysis,
ll six patients (10.9% per lesion) were in the irradiated
Table 2. Serial QCA Analyses (Intention to T
Irrad
(55 L
In-stent
MLD post (mm) 2.66
MLD follow-up (mm) 2.23
Late loss (mm) 0.43
DS follow-up (%) 23
Restenosis, n (%) 7 (1
Edges
Prox MLD post (mm) 2.50
Prox MLD follow-up (mm) 2.49
Prox late loss (mm) 0.01
Prox restenosis, n (%) 0 (0
Distal MLD post (mm) 2.10
Distal MLD follow-up (mm) 1.99
Distal late loss (mm) 0.13
Distal restenosis, n (%) 0 (0
Irradiated segment
MLD (mm) 1.77
DS follow-up (%) 37.87
Restenosis, n (%) 11 (2
Vessel segment
MLD (mm) 1.57
DS follow-up (%) 44
Restenosis rate, n (%) 15 (2
DS  diameter stenosis; MLD  minimal lumen diameter;roup (p  0.03). In a per-protocol analysis, five (9.6%) were in the irradiated group, and one (1.8%) was in the
ontrol group (p 0.10). All occlusions occurred within the
tented segment. The two patients with occlusions outside
he time window of the angiographic follow-up were not
ncluded in the QCA results at six months (Table 2). If
ncluded, the late loss and restenosis rates in the irradiated
roup were 0.51  0.85 mm and 16.4%, respectively. There
ere no patients with a sub-acute thrombosis within the
rst 30 days after the procedure. Of the six total occlusions,
wo were late thrombotic (presented as acute MIs) and four
ere silent. Four of the six patients underwent repeat
evascularization (one surgical and three percutaneous).
NCIDENCE OF GM AND LOCATION OF RESTENOSIS WITH
ESPECT TO THE IRRADIATED SEGMENT. All 55 vessels
ere interpretable for the ascertainment of GM and/or
ocation of restenosis outside the stent and peri-stent
egments. The average length of GM was 4.68  1.80 mm,
ith a range of 1.92 to 7.65 mm. There were 12 (21%)
essels with documented GM (10 proximal and 2 distal). Of
hese, one vessel was occluded, and three had a diameter
tenosis 50%. Two of these were related because of the
M (13% of the overall restenosis observed in the irradiated
roup), and one showed progression of a pre-existing plaque
roximal (12.12 mm) to the irradiated area. Sixty percent of
he GM (7 of 12 vessels) were related to post-radiation
ntervention because of complications (persistent spasm,
ocal thrombus formation, edge dissection) and the other
0% (5 of 12) was the result of inappropriate coverage of the
tented segment by the radiation source. All the later cases
s)
No Irradiation
(53 Lesions) p
4 2.69  0.40 0.68
2 1.85  0.52 0.006
5 0.84  0.46 0.001
30  14 0.07
7 (13.2%) 1.00
1 2.71  0.62 0.09
0 2.37  0.55 0.28
8 0.34  0.50 0.001
1 (1.9%) 1.00
8 2.28  0.45 0.09
1 2.12  0.45 0.21
7 0.16  0.33 0.77
0 (0.0%) 1.00
1 NA NA
49 NA NA
) NA NA
5 1.71  0.45 0.19
33  1.3 0.001
) 8 (15.1%) 0.16
 proximal; QCA  quantitative coronary angiography.reat)
iation
esion
 0.4
 0.8
 0.7
 25
2.7%)
 0.6
 0.6
 0.4
.0%)
 0.5
 0.6
 0.5
.0%)
 0.7
 21.
1.6%
 0.6
 20
7.3%ere marginal, and they were not related to restenosis.
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The BRIDGE Trial August 4, 2004:528–37VUS. The serial IVUS volumetric analysis confirmed the
nhibition of the intra-stent neo-intimal hyperplasia within
he irradiated group when compared with control (10  12
m3 vs. 36  26 mm3; p  0.001) with a concomitant
eduction of the percentage volume obstruction from 21 
4% to 5  6%; p  0.001 (Table 3).
In addition, the change in the plaque behind the stent
truts was greater in the irradiated group (p  0.06) than in
he control. However, at the proximal and distal edges of
he irradiated group, there was an increase in plaque volume
ccompanied by a compensatory increase in the external
lastic membrane volume (expansive remodeling), whereas
oth plaque and external elastic membrane volumes re-
ained unchanged in the control group. The final result was
hat the luminal volume remained unchanged in both
roups at follow-up.
Table 3. IVUS Analyses (Intention to Treat)
Stent
Stent length (mm) Post
Stent volume (mm3) Post
Neo-intimal volume (mm3) F/Up
Change in PBS volumes (mm3) F/Up
Obstruction volume (%) F/Up
Proximal edge
Change in EEM
Change in plaque volume (mm3)
Change in luminal volume (mm3)
Distal edge
Change in EEM
Change in plaque volume (mm3)
Change in luminal volume (mm3)
*Student t test.
EEM  external elastic membrane; F/Up  follow-up; IV
stent struts.
Table 4. Most Severe (Hierarchical) MACE, R
and Total Count of Cardiac Events Up to 12
Death, n (%)
Myocardial infarction
Q-wave, n (%)
Non–Q-wave, n (%)
Revascularization procedures
CABG, n (%)
TLR RPTCA, n (%)
TVSR, non-TLR RPTCA, n (%)
TEVR, non-TLR, non-TVSR RPTCA, n (%)
MACE, n (%)*
Revascularization procedures, n (%) (CABG and
PTCA, event per patient)
Total count of events, n
*Includes death, myocardial infarction, and revascularization.
student t test. Total epicardial vessel revascularization (TEV
artery that was in physical contact with any component (guidi
hardware during the initial (allocated) procedure. Target vess
tion occurring within the treated vessel segment as defined b
CABG coronary artery bypass graft; MACEmajor ad
angioplasty; TLR  target vessel revascularization; RPTCA  repACE. Table 4 shows the hierarchical ranking of MACE
p to 12 months as well as the incidence of revascular-
zation procedures (event per patient and total count of
vents). With the exception of the target lesion revascu-
arization, the control group scored better than the
rradiated group because of less frequent restenosis out-
ide the target site in either the irradiated segment or the
arget vessel segment. The MACE-free survival curves
re presented in Figure 4.
ISCUSSION
he premises of the present trial were that in the stent era,
ith more than 85% to 90% of patients being stented,
adiotherapy treatment has to demonstrate its efficacy as an
djunct to stent treatment of de novo lesions for primary
Irradiation
57 Lesions)
No Irradiation
(57 Lesions) p*
18.2  1.2 18.3  1.8 0.60
156  43 160  45 0.69
10  12 36  26 0.001
24  28 14  37 0.06
5  6 21  14 0.001
4.45  15.82 0.49  10.85 0.23
5.28  13.77 2.40  9.04 0.31
0.84  12.10 1.96  12.77 0.71
4.36  9.33 0.91  9.89 0.15
6.93  7.41 1.73  6.64 0.004
2.56  9.27 0.82  10.67 0.48
intravascular ultrasound; PBS  plaque volume behind the
cularization Procedures (Event Per Patient),
ths
Irradiation
 54 Patients)
No Irradiation
(n  58 Patients) p
0 (0.0) 0 (0.0) 0.36†
3 (5.6) 0 (0.0)
3 (5.6) 3 (5.2)
0 (0.0) 0 (0.0)
2 (3.7) 5 (8.6)
6 (11.1) 1 (1.7)
0 (0.0) 1 (1.7)
14 (25.9) 10 (17.2) 0.36‡
11 (20.4) 7 (12.1) 0.31‡
19 10 0.09§
oxon rank sum test. ‡The Fisher exact test (two-tail). §The
efined as a revascularization of any segment of the coronary
eter, guidewire, balloon catheter, or stent) of the angioplasty
ent revascularization (TVSR) is defined as a revasculariza-
iographic core laboratory analysis.
cardiac events; PTCA percutaneous transluminal coronary(


US evas
Mon
(n
†Wilc
R) is d
ng cath
el segm
y ang
verseeat PTCA.
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August 4, 2004:528–37 The BRIDGE Trialrevention of restenosis. A large percentage of the balloon
geographic miss” cases are the result of balloon dilation
pplied before or after stenting; to avoid this phenomenon,
strategy of direct stenting with post-dilation performed
trictly inside the stent was mandated before any random-
zation. Also, radiation treatment had to be performed as
he last interventional procedure.
An IVUS investigation was performed after stent deploy-
ent to exclude incomplete deployment and apposition
nd/or edge dissection. A centering delivery system and
VUS-guided dosimetry of 20 Gy at 1 mm in the artery wall
ere used to theoretically preclude any radiation failure due
o an insufficient dose administration and/or inhomoge-
eous dose distribution. An effective irradiation source
ength (32 mm) almost twice as long as the stent length (18
m) was used to ensure adequate coverage of the lesion.
nti-thrombotic peri-procedural protection with glycopro-
ein IIb/IIIa inhibitors was systematically applied, and
rolongation of the dual anti-platelet treatment was man-
ated for the prevention of late occlusion.
The main observations made in this study are the
ollowing: In-stent neo-intimal proliferation and restenosis
re significantly reduced by beta irradiation. Peri-stent edge
tenoses are eliminated by proper procedural technique and
ncreased length of irradiation. Despite all efforts to reduce
ascular damage and GM, total vessel analysis documents
ew stenosis toward the edges of the radioactive source (four
ithin the effective irradiated segment, four at the edges).
espite peri-procedural administration of abciximab and
hienopyridin for 11 months, vascular brachytherapy in
atients with new stent implantation is associated with an
xcess of late coronary occlusion.
revious observational and randomized trials with beta-
rachytherapy for de novo lesions. The Proliferation RE-
uction with Vascular ENergy Trial (PREVENT) also used
centered beta-emitting 32P source wire. In this small
lacebo-controlled, dose-finding study, the clinical and
ngiographic outcome was better in the irradiated patients
21). However, edge restenosis reduced the overall clinical
igure 4. Event-free survival curves (Kaplan-Meier) at one year for the
ontrol and irradiated patients. MACE  major adverse cardiac and
erebrovascular events; p(FE)  p value Fisher exact test; p(LR)  p value
og rank test; RR  relative risk.enefit of radiotherapy. A 10% incidence of late vessel ncclusion also was reported with the one-month adminis-
ration of double anti-platelet therapy.
In the Beta Radiation In Europe (BRIE) registry, 149
atients received 14Gy of beta radiation. Restenosis and
ACE rates were 34% (9). In this trial, the problem of
dge restenosis was related to the occurrence of GM (16). A
.7% late vessel occlusion rate was reported, and the
rolongation of anti-platelet treatment reduced its inci-
ence. Patients that received a new stent in combination
ith radiation had worse clinical and angiographic out-
omes than patients who were treated with balloon angio-
lasty and radiotherapy. The same was observed during the
uropean Dose-Finding study (8).
The BetaCath trial was the largest randomized trial of
eta radiation and stenting in de novo lesions (951 patients).
t failed to show any difference in the primary end point in
he radiation arm compared with the control arm (10). The
ate vessel thrombosis, edge restenosis, and the incompati-
ility of radiation with the use of stents for de novo lesions
ere the main lessons learned from this study. However,
his negative result could be attributed to the lack of source
entering, low prescription radiation dose, and the high
ncidence of GM.
dge restenosis. Restenosis at the edges of the radioactive
ource was first described after radioactive stent implanta-
ion and (25) was seen subsequently in all brachytherapy
rials. By IVUS, edge restenosis is a combination of increase
n plaque volume without adaptive remodeling (26,27).
In concordance with known cell biological effects and animal
ata, low-dose radiation at the extremities of the source (dose
all-off) and angioplasty-induced vessel injury, referred to as
geographical miss,” seem to play a key role in edge restenosis
nd treatment failure for beta (16) and gamma (28) brachy-
herapy. The fall-off dose at the source edges is an inherent
haracteristic of all sources, beta or gamma.
afety margins. The safety margins after brachytherapy for
voidance of GM and edge restenosis have not yet been
efined. Many factors, such as the extent of the peri-vascular
njury (up to 10 mm away from a microscopic point of view)
29), the barotrauma caused by the balloons (up to 2.5 mm
way from the actual stent margins) (30), the source displace-
ent during the cardiac cycle (up to 5.4 mm) (31), and the
all-off dose at the margins of each source, must be considered.
It has been proposed that for an 18-mm lesion treated with
20-mm balloon, a 39-mm iridium source should be used
32). In an animal model, a safety margin of 14.5 mm was
ufficient to eliminate edge restenosis (33). Recently a 10-mm
afety margin per vessel was found to have 95% specificity for
voidance of GM (34). As a simple rule, a ratio of one to two
or the lesion to source length is advised. This advice was
pplied in the present trial, with the result of eliminating any
ignificant loss in the peri-stent segment (5 mm proximal, 5
m distal). However, eight sites of restenosis were docu-
ented around the edges of the irradiated area. The physio-
athological mechanism of narrowing remains elusive because
o injury has been imparted on this vessel wall segment, and
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The BRIDGE Trial August 4, 2004:528–37he spiraled balloon of the radiation therapy delivery system
annot be implicated in a potential traumatic injury, because it
s slightly undersized, inflated at low pressure, and shorter than
he radioactive source (centering balloon length 32 mm and
adiation source length 40 mm [2  20 mm]). The only
emaining explanatory hypothesis is the potential stimulating
ffect of a low dose on a pre-existing atherosclerotic plaque
35). Low-dose radiation (2 Gy) has been shown to poten-
iate cellular metabolic activities and immunological responses
n various tissues (36–39).
ate vessel occlusion. In the first brachytherapy trials, the
henomenon of late occlusion, silent or symptomatic, of the
rradiated vessel became apparent (15). Initial clinical trials
rescribed a combined anti-thrombotic treatment (aspirin
nd clopidogrel or ticlopidine) for two to four weeks after
rradiation. First, they reported that most events occurred
fter discontinuation of the double anti-platelet treatment
9). In consequence, prolonged combined anti-thrombotic
reatment was recommended. Two trials have addressed the
ssue of prolonged anti-platelet treatment for the prevention
f late occlusion/thrombosis. In the Washington Radiation
or In-Stent Restenosis trial (WRIST) (18), clopidogrel and
spirin were prescribed for 6 months (WRIST PLUS), and
n WRIST 12 (19) for 12 months. Both showed good
esults at 6 months follow-up, but at 15 months, the
ncidence of occlusion/thrombotic rates were unacceptably
igh: 15.9% in WRIST PLUS and 13.5% in WRIST 12.
econd, they reported that new stent implantation was
elated to late thrombosis both in de novo (40) and
estenotic lesions (9,10).
In the present study, six late occlusions occurred despite the
se of prolonged dual anti-platelet treatment. Poor compliance
ith anti-platelet medication, edge dissection, and incomplete
tent apposition at baseline were excluded as direct mecha-
isms of thrombosis or occlusion. The most likely explanation
s long-term endothelial dysfunction and delayed vascular
ealing, two established drawbacks of vessel irradiation previ-
usly documented in animal models (41).
tudy limitations. This study is a well-randomized study
ut not a double-blind trial, and the effect of a sham source
n injured coronary segments has not been evaluated. Stent
mplantation was considered as the only source of injury.
inor injuries from guiding catheters, guide wires, or the
adiation-centering catheter cannot be completely ruled out.
onclusions. Optimized application of vascular brachy-
herapy with adequate coverage of vascular injury and use of
VUS-guided dosimetry did succeed in preventing in-stent
eo-intimal proliferation and peri-stent edge restenosis.
owever, the lower doses that are delivered at the fall-off
ones, which is a phenomenon inherent in any brachyther-
py source (short or long), seems to promote the progression
f pre-existing plaque and results in new stenoses toward
he edges of the irradiated segment. The increased radiation
ource length and dose were most likely responsible for the
bserved excess in vessel thrombosis despite prolonged
nti-platelet medication. This narrow therapeutic windowrecludes any use of brachytherapy as a therapeutic tool for
he primary prevention of restenosis in de novo lesions
reated with bare metal stents.
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erruys, Erasmus Medical Center, Thoraxcenter, Bd-406, Dr.
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